Efficacy and Safety of Brodalumab In Patients With Moderate To Severe Plaque Psoriasis: Results of AMAGINE-1, a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

被引：0
|
作者：
Papp, K. [1 ]
Reich, K. [2 ]
Blauvelt, A. [3 ]
Baran, W. [4 ]
Bolduc, C. [5 ,6 ]
Toth, D. [7 ,8 ]
Gottlieb, A. B. [9 ]
Thaci, D. [10 ]
Li, J. [11 ]
Nirula, A. [11 ]
机构：
[1] Prob Med Res, Waterloo, ON, Canada
[2] Dermatologikum Hamburg, Hamburg, Germany
[3] Oregon Med Res Ctr, Portland, OR USA
[4] Wroclaw Med Univ, Wroclaw, Poland
[5] Univ Montreal, Montreal, PQ, Canada
[6] Innovaderm Res, Montreal, PQ, Canada
[7] XLR8 Med Res, Windsor, ON, Canada
[8] Prob Med Res, Windsor, ON, Canada
[9] Tufts Med Ctr, Boston, MA USA
[10] Med Univ Lubeck, D-23538 Lubeck, Germany
[11] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2015年 / 135卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
043
引用
收藏
页码：S8 / S8
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis: Results of AMAGINE-1, a phase 3, randomized, double-Blind, placebo-controlled study
    Papp, Kim
    Reich, Kristian
    Leonardi, Craig
    Paul, Carle
    Blauvelt, Andrew
    Baran, Wojciech
    Bolduc, Chantal
    Toth, Darryl
    Langley, Richard G.
    Cather, Jennifer
    Gottlieb, Alice
    Thaci, Diamant
    Milmont, Cassandra E.
    Lim, Joanne
    Klekotka, Paul
    Kricorian, Greg
    Nirula, Ajay
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S8 - S8
  • [2] Efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis: Results of AMAGINE-1, a phase 3, randomized, double-blind, placebo-controlled study through week 12
    Papp, Kim
    Reich, Kristian
    Leonardi, Craig
    Paul, Carle
    Blauvelt, Andrew
    Baran, Wojciech
    Bolduc, Chantal
    Toth, Darryl
    Langley, Richard
    Cather, Jennifer
    Gottlieb, Alice
    Thaci, Diamant
    Milmont, Cassandra
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB233 - AB233
  • [3] AMAGINE-1: a phase 3, randomized, double-blind, placebo-controlled study of brodalumab in subjects with psoriasis
    Papp, K.
    Reich, K.
    Leonardi, C.
    Paul, C.
    Blauvelt, A.
    Baran, W.
    Bolduc, C.
    Toth, D.
    Langley, R. G.
    Cather, J.
    Gottlieb, A. B.
    Thaci, D.
    Milmont, C. E.
    Li, J.
    Klekotka, P.
    Kricorian, G.
    Nirula, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (06) : E119 - E120
  • [4] Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double-blind, placebo-controlled study
    Seo, Seong Jun
    Shin, Bong Seok
    Lee, Joo-Heung
    Jeong, Haeyoun
    JOURNAL OF DERMATOLOGY, 2021, 48 (06): : 807 - 817
  • [5] A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
    Papp, K. A.
    Reich, K.
    Paul, C.
    Blauvelt, A.
    Baran, W.
    Bolduc, C.
    Toth, D.
    Langley, R. G.
    Cather, J.
    Gottlieb, A. B.
    Thaci, D.
    Krueger, J. G.
    Russell, C. B.
    Milmont, C. E.
    Li, J.
    Klekotka, P. A.
    Kricorian, G.
    Nirula, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2016, 175 (02) : 273 - 286
  • [6] Efficacy and safety of adalimumab in Chinese patients with moderate to severe plaque psoriasis: Results from a phase 3, randomized, placebo-controlled, double-blind Study
    Zhang, Jianzhong
    Gu, Jun
    Zheng, Jie
    Zheng, Min
    Wang, Gang
    Gu, Yihua
    Okun, Martin
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB232 - AB232
  • [7] The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study
    Zhang, JianZhong
    Tsai, Tsen-Fang
    Lee, Min-Geol
    Zheng, Min
    Wang, Gang
    Jin, HongZhong
    Gu, Jun
    Li, RuoYu
    Liu, QuanZhong
    Chen, Jin
    Tu, CaiXia
    Qi, ChunMei
    Zhu, Hua
    Ports, William C.
    Crook, Tim
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2017, 88 (01) : 36 - 45
  • [8] Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study
    Cai, L.
    Gu, J.
    Zheng, J.
    Zheng, M.
    Wang, G.
    Xi, L. -Y.
    Hao, F.
    Liu, X. -M.
    Sun, Q. -N.
    Wang, Y.
    Lai, W.
    Fang, H.
    Tu, Y. -T.
    Sun, Q.
    Chen, J.
    Gao, X. -H.
    Gu, Y.
    Teixeira, H. D.
    Zhang, J. -Z.
    Okun, M. M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (01) : 89 - 95
  • [9] Improvements in depression and anxiety with brodalumab therapy in AMAGINE-1, a phase 3 study for moderate to severe plaque psoriasis
    Papp, Kim
    Reich, Kristian
    Paul, Carle
    Blauvelt, Andrew
    Toth, Darryl
    Langley, Richard G.
    Cather, Jennifer
    Gottlieb, Alice
    Li, Joanne
    Kricorian, Gregory
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB254 - AB254
  • [10] Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study
    Van Voorhees, Abby S.
    Gold, Linda Stein
    Lebwohl, Mark
    Strober, Bruce
    Lynde, Charles
    Tyring, Stephen
    Cauthen, Ashley
    Sofen, Howard
    Zhang, Zuoshun
    Paris, Maria
    Wang, Yao
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (01) : 96 - 103
12345